Baxter Sees Promising Results in Inhibitor Treatment Trial

Baxter International Inc. announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa (rFVIIa) treatment for people with Hemophilia A or B who develop inhibitors.The prospective, open-label, randomized, multicenter trial was designed to assess the safety and efficacy of BAX 817 in male […]